Table 1.
Demographic and clinical characterization of the cohort.
| Parameter | N or mean (% or range) |
|---|---|
| Gender, n (%) | |
| Female | 22 (48) |
| Male | 24 (52) |
| Age, years (range) | 69 (41–96) |
| Underlying diseases, n (%) | |
| Autoimmune Disease | 3 (6) |
| Immunosuppressed | 2 (4) |
| Cancer history | 7 (15) |
| Chemotherapy | 1 (2) |
| Hypertension | 31 (67) |
| Diabetes | 18 (39) |
| COPD | 3 (7) |
| Asthma | 2 (4) |
| Other respiratory disease | 4 (9) |
| Chronic Liver Disease (Child B) | 1 (2) |
| Chronic Kidney Disease | 7 (15) |
| Symptoms | |
| Days of symptoms before admission | 7.41 (0–21) |
| Cough before admission | 28 (61) |
| Dyspnea before admission | 22 (48) |
| Fever before admission | 27 (59) |
| Reasons for admission | |
| Hypoxemia | 30 (65) |
| Relevant Constitutional Symptoms | 4 (9) |
| Vomiting and Diarrhea with electrolyte imbalance | 2 (4) |
| Other medical conditions | 7 (15) |
| Surgical conditions | 3 (7) |
| Stage of disease at admission | |
| Stage I | 5 (11) |
| Stage IIa | 11 (23) |
| Stage IIb | 27 (59) |
| Stage III | 3 (7) |
| Treatment | |
| Patients supported with non-invasive ventilation at any point | 12 (26) |
| Patients supported with invasive ventilation at any point | 6 (13) |
| No medication to the infection | 10 (22) |
| Hydroxychloroquine (monotherapy) | 9 (20) |
| Hydroxychloroquine + azithromycin | 19 (41) |
| Hydroxychloroquine + Lopinavir + Ritonavir | 3 (7) |
| Azithromycin (monotherapy) | 1 (2) |
| Any of the above + corticosteroids | 6 (13) |
| Corticosteroids (monotherapy) | 4 (9) |
| Outcome | |
| Deaths | 5 (11) |
| Cured | 41 (89) |
COPD, Chronic Obstructive Pulmonary Disease.